- Home
- CMPX vs NGNE Comparison
CMPX vs NGNE Comparison
Compare CMPX & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- NGNE
- Stock Information
- Founded
- CMPX 2014
- NGNE 2003
- Country
- CMPX United States
- NGNE United States
- Employees
- CMPX N/A
- NGNE N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- NGNE Health Care
- Exchange
- CMPX Nasdaq
- NGNE Nasdaq
- Market Cap
- CMPX 291.8M
- NGNE 325.3M
- IPO Year
- CMPX N/A
- NGNE N/A
- Fundamental
- Price
- CMPX $3.51
- NGNE $17.71
- Analyst Decision
- CMPX Strong Buy
- NGNE Strong Buy
- Analyst Count
- CMPX 8
- NGNE 7
- Target Price
- CMPX $13.50
- NGNE $41.86
- AVG Volume (30 Days)
- CMPX 876.2K
- NGNE 133.6K
- Earning Date
- CMPX 11-11-2025
- NGNE 11-14-2025
- Dividend Yield
- CMPX N/A
- NGNE N/A
- EPS Growth
- CMPX N/A
- NGNE N/A
- EPS
- CMPX N/A
- NGNE N/A
- Revenue
- CMPX N/A
- NGNE N/A
- Revenue This Year
- CMPX N/A
- NGNE N/A
- Revenue Next Year
- CMPX N/A
- NGNE N/A
- P/E Ratio
- CMPX N/A
- NGNE N/A
- Revenue Growth
- CMPX N/A
- NGNE N/A
- 52 Week Low
- CMPX $1.27
- NGNE $6.88
- 52 Week High
- CMPX $4.08
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- CMPX 59.49
- NGNE 38.90
- Support Level
- CMPX $3.37
- NGNE $17.13
- Resistance Level
- CMPX $3.77
- NGNE $20.72
- Average True Range (ATR)
- CMPX 0.19
- NGNE 1.29
- MACD
- CMPX 0.01
- NGNE -0.18
- Stochastic Oscillator
- CMPX 46.87
- NGNE 16.20
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.